Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatment of HNSCCs, mainly in combination with standard chemotherapy. This review focuses on the results of the main phase III studies evaluating ICIs in recurrent or metastatic HNSCCs. The efficacy and indications according to the PD-L1 status, the main predictive biomarker, are discussed. The results of trials assessing ICI efficacy for locally advanced disease, including the neoadjuvant setting are also discussed. Finally, therapeutic combinations that are potential treatments for HNSCCs, including ICIs and targeted therapies such as anti-EGFR agents, are presented.

[1]  M. Xu,et al.  Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications , 2023, Cancers.

[2]  R. Ferris,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2023, JAMA oncology.

[3]  E. Yilmaz,et al.  Immunotherapy in HPV-Related Oropharyngeal Cancers , 2023, Current Treatment Options in Oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[5]  J. Machiels,et al.  Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Prevost,et al.  Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Kyung-Han Lee,et al.  Metabolic parameters on baseline 18F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma , 2022, Frontiers in Medicine.

[8]  J. Machiels,et al.  LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) , 2022, Annals of Oncology.

[9]  A. Hansen,et al.  651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study , 2022, Annals of Oncology.

[10]  D. Kawakita,et al.  Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors , 2022, Scientific Reports.

[11]  J. Lunceford,et al.  Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[12]  K. Harrington,et al.  Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 , 2022, The oncologist.

[13]  P. Pérez-Segura,et al.  NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER: RATIONALE, CURRENT EVIDENCE AND FUTURE PERSPECTIVE. , 2021, Critical reviews in oncology/hematology.

[14]  F. Clatot,et al.  Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. , 2021, European journal of cancer.

[15]  J. Machiels,et al.  A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. , 2021, European journal of cancer.

[16]  N. Muhanna,et al.  Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis. , 2021, JAMA otolaryngology-- head & neck surgery.

[17]  C. Borel,et al.  LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial , 2021, Annals of Oncology.

[18]  J. Taube,et al.  Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial , 2021, Journal for ImmunoTherapy of Cancer.

[19]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[20]  R. Ferris,et al.  Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  S. Rossi,et al.  Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT , 2019, The Journal of Nuclear Medicine.

[22]  T. Day,et al.  Impact of PD‐L1 expression and human papillomavirus status in anti‐PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—Systematic review and meta‐analysis , 2019, Head & neck.

[23]  F. Bidault,et al.  Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2019, European journal of cancer.

[24]  I. Braña,et al.  Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial , 2019, JAMA oncology.

[25]  A. Jimeno,et al.  Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. , 2019, European journal of cancer.

[26]  J. Humm,et al.  Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  K. Mayawala,et al.  Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. , 2018, Oral oncology.

[28]  Jonathan C. Cheng,et al.  Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.

[29]  K. Harrington,et al.  Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. , 2018, Oral oncology.

[30]  L. Alemany,et al.  Human papillomavirus-related oropharyngeal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. Mansfield,et al.  Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.